The Wahl Lab focuses on the development of PET and radiotherapeutic agents for the diagnosis and therapy of hematological and other malignancies. Our goal is to complete preclinical studies and to quickly translate appropriate targeted radio-labeled agents to clinical use.
The lab, led by Richard L. Wahl, MD, features a team of researchers focused on developing and improving targeted imaging and therapy for cancer using radionuclide-based approaches.
Preclinical and clinical studies, including clinical trials, are undertaken in the Wahl Lab. A secondary focus is clinical imaging of brown adipose tissue activation in man.